ORKA on Nasdaq

Oruka Therapeutics, Inc.

American pharmaceutical preparations company based in Westminster. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerORKA on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersWestminster, United States2
  • Incorporated inDE3
  • Business address855 Oak Grove Ave., Suite 100, Menlo Park, Ca 940253
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI529900TG7O4ESUDMGI542
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 37779162

See how the biggest companies compare on our leaderboards

PsO and will evaluate three dose levels of ORKA-001: 37.5 mg at Week 0, 300 mg at Weeks 0 and 4, and 600 mg at Weeks 0 and 4, versus placebo.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-14.4%Return on equity5
-$5.0MFree cash flow5

Financial statements

Revenue67895$0 in 2023
02019: $0$020192020: $0$020202021: $0$020212022: $0$020222023: $0$02023
Operating income7895-$7.3M in 2023+25% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$5.8M-$5.8M20192020: -$9.8M-$9.8M2020+68%2021: -$19.3M-$19.3M2021+98%2022: -$10.6M-$10.6M2022−45%2023: -$7.3M-$7.3M2023−31%
Net income7895-$5.3M in 2023−3% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$5.5M-$5.5M20192020: -$9.7M-$9.7M2020+78%2021: -$19.3M-$19.3M2021+98%2022: -$9.9M-$9.9M2022−49%2023: -$5.3M-$5.3M2023−46%

Every line of the income statement as filed: the last 2 fiscal years, latest first.12

Period ending2025-12-312024-12-31
Research and development$100.6M$75.1M
General and administrative$21.4M$13.1M
Total operating expenses$122.1M$88.1M
Loss from operations-$122.1M-$88.1M
Interest income$16.6M$5.9M
Interest expense-$1.5M
Other income (expense), net-$12.0K$4.0K
Total other income, net$16.6M$4.4M
Net loss-$105.4M-$83.7M

Compare Oruka Therapeutics, Inc. with another company

Leadership

Who has led Oruka Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Richard B. Brewer2009
  2. Michael R. Bristow2009–2021
  3. Lawrence Otto Klein2024–now

President

  1. Ted W. Love2006
  2. Richard B. Brewer2009
  3. Michael R. Bristow2009–2015
  4. Lawrence Otto Klein2024

Chief financial officer

  1. Henry Ward Wolff2006–2007
  2. E. Lee Bendekgey2008–2009
  3. Kathryn E. Falberg2009
  4. Patrick M. Wheeler2009–2014
  5. C. Jeffrey Dekker2021–2022

Chief operating officer

  1. Kathryn E. Falberg2009
  2. Thomas A. Keuer2014–2022
  3. Laura Lee Sandler2025–now
2010201520202025
Board members and other officers (37)

Former names

  • ARCA biopharma, Inc.Jan 28, 2009 to Aug 30, 20243
  • NUVELO INCFeb 4, 2003 to Jan 27, 20093
  • HYSEQ INCJul 17, 1997 to Jan 28, 20033

Timeline

  1. Sep 6, 2024New chief executive Lawrence Otto Klein becomes CEO13
  2. Oct 15, 2009New chief executive Michael R. Bristow becomes CEO15
  3. Feb 5, 2009New chief executive Richard B. Brewer becomes CEO14

Filings

332 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 53 major events, 127 insider forms, 47 large holders, 85 other. The latest 20:

  1. Oct 15, 2026144 EDGAR
  2. Oct 15, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  3. Oct 13, 2026144 EDGAR
  4. Oct 13, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  5. Oct 2, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  6. Oct 1, 2026144 EDGAR
  7. Sep 21, 2026144 EDGAR
  8. Sep 21, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  9. Sep 21, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  10. Sep 15, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  11. Sep 15, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  12. Sep 15, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  13. Sep 15, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  14. Sep 15, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  15. Sep 1, 2026144 EDGAR
  16. Sep 1, 2026144 EDGAR
  17. Sep 1, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  18. Sep 1, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  19. Aug 28, 2026424B5 PROSPECTUS EDGAR
  20. Aug 27, 2026EFFECT EDGAR

The 332 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

83 open-market trades by officers, directors and large owners since October 2021: 42 buys and 41 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 21, 2026Agarwal ArjunSenior Vice President, FinanceSale533$95.75$51.0KForm 4
Sep 21, 2026Quinlan Paul TGeneral CounselSale10,000$93.64$936.4KForm 4
Sep 15, 2026Goncalves JoanaChief Medical OfficerSale7,947$92.38$734.2KForm 4
Sep 15, 2026Agarwal ArjunSenior Vice President, FinanceSale560$95.71$53.6KForm 4
Sep 15, 2026Klein Lawrence OttoChief Executive OfficerSale2,452$95.71$234.7KForm 4
Sep 15, 2026Quinlan Paul TGeneral CounselSale1,039$95.71$99.4KForm 4
Sep 15, 2026Sandler Laura LeeChief Operating OfficerSale906$95.71$86.7KForm 4
Sep 11, 2026Agarwal ArjunSenior Vice President, FinanceSale9,459$92.23$872.4KForm 4
Sep 1, 2026Sandler Laura LeeChief Operating OfficerSale5,000$91.82$459.1KForm 4
Sep 1, 2026Klein Lawrence OttoChief Executive OfficerSale75,000$91.84$6.9MForm 4
Aug 17, 2026Goncalves JoanaChief Medical OfficerSale7,000$111.84$782.9KForm 4
Aug 14, 2026Quinlan Paul TGeneral CounselSale52,000$108.49$5.6MForm 4
Aug 13, 2026Agarwal ArjunSenior Vice President, FinanceSale10,000$106.66$1.1MForm 4
Jul 15, 2026Goncalves JoanaChief Medical OfficerSale7,000$86.28$604.0KForm 4
Jul 13, 2026Agarwal ArjunSenior Vice President, FinanceSale9,999$84.63$846.2KForm 4
Jul 1, 2026Kiselak TomasDirectorSale3,553,410$84.43$300.0MForm 4
Jul 1, 2026Sandler Laura LeeChief Operating OfficerSale5,000$94.42$472.1KForm 4
Jun 22, 2026Agarwal ArjunSenior Vice President, FinanceSale1,587$80.95$128.5KForm 4
Jun 15, 2026Agarwal ArjunSenior Vice President, FinanceSale395$69.69$27.5KForm 4
Jun 15, 2026Goncalves JoanaChief Medical OfficerSale7,947$69.28$550.6KForm 4

All 83 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC9,057,645$862.0M0.0%+1,626,242
BlackRock, Inc.4,990,181$474.9M0.0%+1,463,094
Venrock Adviser, LLC4,148,428$394.8M12.0%No change
Fairmount Funds Management LLC3,705,262$352.6M23.3%No change
Capital World Investors3,401,639$323.7M0.0%New
Rtw Investments, LP3,139,030$298.7M2.6%+1,080,882
State Street Corp2,673,090$254.4M0.0%+1,059,629
Vanguard Capital Management LLC2,360,971$224.7M0.0%+501,340
Paradigm Biocapital Advisors LP2,144,526$204.1M3.8%−175,790
Deep Track Capital, LP1,926,000$183.3M2.7%−108,203
Bellevue Group AG1,657,190$157.7M3.3%+1,150,182
Franklin Resources Inc1,621,451$154.3M0.0%+617,395
Remedium Capital Partners, LLC1,565,661$149.0M33.0%No change
Ra Capital Management, L.P.1,554,597$148.0M1.3%New
Viking Global Investors LP1,503,478$143.1M0.4%−1,163,212
Geode Capital Management, LLC1,429,954$136.1M0.0%+475,087
Jupiter Topco LLC1,375,844$131.0M0.1%New
Perceptive Advisors LLC1,345,063$128.0M2.0%−50,438
Polar Capital Holdings Plc1,228,609$116.9M0.3%+180,916
Citadel Advisors LLC1,119,011$106.5M0.1%+111,474
Bnp Paribas Financial Markets1,079,015$102.7M0.1%+1,068,087
Avidity Partners Management LP760,424$72.4M11.6%−760,424
Summit Partners Public Asset Management, LLC658,301$62.7M1.6%New
Aberdeen Group plc646,943$61.6M0.1%+571,263
UBS Group AG639,363$60.8M0.0%+427,092

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73